Corcept Therapeutics Incorporated
$63.62-$1.36 (-2.1%)
Last close · Data as of Nov 20, 2026
- Market cap
- $8.0B
- P/E
- 80.7x
- EV / EBITDA
- 66.1x
- Revenue
- $761.4M
- Net margin
- 13.1%
- ROCE
- 6.7%
Price chart
Technical chartScreen technicals →This period includes a one-day price step on 31 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -45.4%
- 3M
- -47.4%
- 6M
- +7.7%
- 1Y
- Hidden
- 5Y
- Hidden
- This period includes a one-day price step on 31 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
This period includes a one-day price step on 31 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Day change -$1.36 (-2.1%) from $64.98 to $63.62 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in CORT, bought on each weekday since 2021.
News & filings
What Corcept Therapeutics Incorporated filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernOperating margin fell for three years, from 22.2% to 5.9%.
Strengths (1)
- Return on equity of 15.4% against a peer median of 8.0%.
- This period includes a one-day price step on 31 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Read moreShow less
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Shares outstanding
- 104.9M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $8.0B
- P/E
- 80.7x
- P/B
- 12.4x
- EV / EBITDA
- 66.1x
- EV / Sales
- 10.4x
- P/S
- 10.6x
- 52-week highThis period includes a one-day price step on 31 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
- Hidden
- 52-week lowThis period includes a one-day price step on 31 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
- Hidden
Profitability
- Operating margin
- 5.9%
- Net margin
- 13.1%
- EBITDA margin
- 15.2%
- ROE
- 15.4%
- ROCE
- 6.7%
- ROA
- 11.9%
- Asset turnover
- 0.91
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $761.4M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 12.8%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 23.7%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -29.4%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $141.8M
Solvency
- Current ratio
- 2.92
- Debt / Equity
- 0.01
- Debt / Assets
- 0.01
- CFO / Net profit
- 1.42
- Cash / Market cap
- 1.5%
Where the revenue went
Of every $100 of FY2025 revenue, $13 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $13.0M |
| Revenue | Gross profit | $748.4M |
| Gross profit | Research and development | $254.9M |
| Gross profit | Selling, general and administrative | $448.7M |
| Gross profit | Operating income | $44.8M |
| Operating income | Pretax income | $44.8M |
| Interest and other income | Pretax income | $21.7M |
| Pretax income | Net income | $66.5M |
| Tax benefit and other | Net income | $33.2M |
Revenue and net profit
Revenue grew 12.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $401.9M | $101.4M |
| FY2023 | $482.4M | $106.1M |
| FY2024 | $675.0M | $141.2M |
| FY2025 | $761.4M | $99.7M |
Cash flows
FY2025: $142.0M from operations, $141.8M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $120.3M | $119.9M |
| FY2023 | $126.7M | $126.5M |
| FY2024 | $198.3M | $196.1M |
| FY2025 | $142.0M | $141.8M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $761.4M+12.8%1Y
- Net profit
- $99.7M-29.4%1Y
- Cash from operations
- $142.0M-28.4%1Y
- Free cash flow
- $141.8M-27.7%1Y
- Revenue CAGR, 3Y
- 23.7%
- Net profit CAGR, 3Y
- -0.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $761.4M | — | $99.7M | $141.8M | 15.4% | +12.8% | -29.4% |
Monthly returns
Month-by-month returns of CORT across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $836.6M |
| Current assets | $485.5M |
| Non-current assets | $351.2M |
| Liabilities | $188.8M |
| Current liabilities | $166.1M |
| Non-current liabilities | $22.8M |
| Equity | $647.8M |
| Paid-in capital | $968.6M |
| Retained earnings | $643.4M |
| Treasury stock | $966.6M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; CORT highlighted.
P/E against peers
CORT trades at 80.7x earnings against a peer median of 21.8x (a 269% premium).
Not shown (no positive earnings and no EV / Sales): Charles River Laboratories International, Inc., Glaukos Corporation, Protagonist Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Corcept Therapeutics IncorporatedCORTthis companyP/E ↑ premium | $8.0B | 80.7x | 12.4x | 15.4% | 66.1x |
| Krystal Biotech, Inc.KRYS | $9.1B | 44.3x | 7.4x | 16.8% | 51.2x |
| Charles River Laboratories International, Inc.CRL | $8.9B | — | 2.8x | -4.6% | 27.5x |
| Henry Schein, Inc.HSIC | $8.7B | 21.8x | 2.7x | 12.3% | 12.4x |
| Bio-Techne CorporationTECH | $8.3B | 113.5x | 4.3x | 3.8% | 39.7x |
| Alkermes plcALKS | $7.2B | 29.9x | 4.0x | 13.3% | 20.9x |
| Glaukos CorporationGKOS | $7.1B | -38.1x | 10.9x | -28.6% | -49.0x |
| Protagonist Therapeutics, Inc.PTGX | $6.6B | -50.8x | 10.8x | -21.2% | -41.4x |
| TG Therapeutics, Inc.TGTX | $6.2B | 13.9x | 9.6x | 69.0% | 47.5x |
| Peer median | — | 21.8x | 5.9x | 8.0% | 24.2x |
Year-to-date ROI
CORT since 1 January, against earlier years.
Historical volatility
CORT's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 28.0% |
| FY2023 | 22.2% |
| FY2024 | 20.3% |
| FY2025 | 5.9% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $761.4M |
| Cost of revenueCost Of Revenue | $13.0M |
| Gross profitGross Profit | $748.4M |
| Operating expensesOperating Expense | $703.6M |
| Research and developmentResearch And Development | $254.9M |
| Selling, general and administrativeSelling General And Administration | $448.7M |
| Total expensesTotal Expenses | $716.6M |
| Operating incomeOperating Income | $44.8M |
| Interest and other | |
| Pretax incomePretax Income | $66.5M |
| TaxTax Provision | -$33.2M |
| Net incomeNet Income | $99.7M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $836.6M |
| Current assetsCurrent Assets | $485.5M |
| Non-current assetsTotal Non Current Assets | $351.2M |
| LiabilitiesTotal Liabilities Net Minority Interest | $188.8M |
| Current liabilitiesCurrent Liabilities | $166.1M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $22.8M |
| EquityTotal Equity Gross Minority Interest | $647.8M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $142.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $142.0M |
| Net income, continuing operationsNet Income From Continuing Operations | $99.7M |
| Depreciation and amortisationDepreciation And Amortization | $1.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $1.9M |
| Depreciation | $1.9M |
| Amortization cash flowAmortization Cash Flow | — |
| Amortization of intangiblesAmortization Of Intangibles | — |
| Amortization of securitiesAmortization Of Securities | -$5.1M |
| Stock-based compensationStock Based Compensation | $84.5M |
| Deferred taxDeferred Tax | -$37.5M |
| Deferred income taxDeferred Income Tax | -$37.5M |
| Change in working capitalChange In Working Capital | -$1.4M |
| Other non-cash itemsOther Non Cash Items | — |
| Investing cash flowInvesting Cash Flow | $69.8M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $69.8M |
| Capital expenditureCapital Expenditure | -$210.0k |
| Purchase of PP&EPurchase Of PPE | -$210.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$210.0k |
| Purchase of investmentsPurchase Of Investment | -$319.6M |
| Sale of investmentsSale Of Investment | $389.6M |
| Net investment purchases and salesNet Investment Purchase And Sale | $70.0M |
| Financing cash flowFinancing Cash Flow | -$220.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$220.4M |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Common stock repurchasedCommon Stock Payments | $0.00 |
| Share buybacksRepurchase Of Capital Stock | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | -$147.4M |
| Other financing chargesNet Other Financing Charges | -$72.9M |
| Change in cashChanges In Cash | -$8.6M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 144.0% |
| Cash at the start of the yearBeginning Cash Position | $127.7M |
| Cash at the end of the yearEnd Cash Position | $120.5M |
| Free cash flowFree Cash Flow | $141.8M |
| Supplemental |
Learn while you research
Academy chapters picked for Corcept Therapeutics Incorporated and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 80.7, learn when high multiples are justified.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read